Market closedNon-fractional
PAVmed/PAVM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About PAVmed
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Ticker
PAVM
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
New York, United States
Employees
107
Website
www.pavmed.com
PAVmed Metrics
BasicAdvanced
$6.7M
Market cap
-
P/E ratio
-$9.12
EPS
0.83
Beta
-
Dividend rate
Price and volume
Market cap
$6.7M
Beta
0.83
Financial strength
Current ratio
0.538
Quick ratio
0.508
Long term debt to equity
-13.677
Total debt to equity
-241.492
Interest coverage (TTM)
-147.94%
Management effectiveness
Return on assets (TTM)
-76.10%
Return on equity (TTM)
1,546.64%
Valuation
Price to revenue (TTM)
1.828
Price to book
-0.1
Price to tangible book (TTM)
-0.09
Price to free cash flow (TTM)
-0.112
Growth
Revenue change (TTM)
375.71%
Earnings per share change (TTM)
-38.20%
3-year earnings per share growth
4.29%
What the Analysts think about PAVmed
Analyst Ratings
Majority rating from 4 analysts.
PAVmed Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
0.00%
Net income
-$15M
8.57%
Profit margin
-1,520.00%
8.57%
PAVmed Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.10
-$2.40
-$1.81
-$2.62
-
Expected
-$2.85
-$2.05
-$1.89
-$1.67
-$1.45
Surprise
-26.32%
17.07%
-4.23%
56.57%
-
PAVmed News
AllArticlesVideos
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
PRNewsWire·4 days ago
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
PRNewsWire·3 weeks ago
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
PRNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PAVmed stock?
PAVmed (PAVM) has a market cap of $6.7M as of July 06, 2024.
What is the P/E ratio for PAVmed stock?
The price to earnings (P/E) ratio for PAVmed (PAVM) stock is 0 as of July 06, 2024.
Does PAVmed stock pay dividends?
No, PAVmed (PAVM) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next PAVmed dividend payment date?
PAVmed (PAVM) stock does not pay dividends to its shareholders.
What is the beta indicator for PAVmed?
PAVmed (PAVM) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell PAVmed stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.